{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:24:04Z","timestamp":1791440644411,"version":"4.3.3"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cardiometabolic outcomes were investigated 3 years after switching to the 2-drug regimen dolutegravir\/lamivudine (DTG\/3TC) vs continuing 3-\/4-drug tenofovir alafenamide (TAF)\u2013based regimens in a multicenter phase 3 noninferiority study based on an open-label randomized design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>Adults with virologically suppressed HIV-1 switched to once-daily DTG\/3TC (n = 369) or continued TAF-based regimens (n = 372). Cardiometabolic health parameters were assessed through week 144 via mixed-model repeated measures or logistic regression analyses, adjusting for baseline variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 144, 13% (42\/316) of the DTG\/3TC group and 12% (37\/303) of the TAF-based regimen group had \u226510% weight gain from baseline (adjusted odds ratio, 1.11; 95% CI, .68\u20131.80). Adjusted change from baseline in serum leptin, a surrogate marker of adiposity, was similar between groups (treatment ratio, 1.00; 95% CI, .89\u20131.13). The lipid profile generally favored DTG\/3TC in the baseline boosted subgroup. Adjusted odds revealed no clinically meaningful differences between groups: homeostatic model assessment of insulin resistance \u22652 (adjusted odds ratio, 0.79; 95% CI, .50\u20131.26), metabolic syndrome (International Diabetes Federation criteria, 0.99; .59\u20131.68), hepatic fibrosis (fibrosis-4 index score \u22651.45, 1.39; .63\u20133.06), and coronary artery disease risk (Framingham risk score \u226510%, 0.92; .56\u20131.49). Baseline variables and characteristics associated with odds of each cardiometabolic parameter outcome were consistent with known risk factors, including age, sex, race, and some disease characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cardiometabolic health 3 years after switching to DTG\/3TC was comparable to that for individuals continuing TAF-based regimens, further supporting DTG\/3TC as a robust switch option with a stable metabolic profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov NCT03446573<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad359","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T20:47:47Z","timestamp":1689108467000},"source":"Crossref","is-referenced-by-count":10,"title":["Cardiometabolic Parameters 3 Years After Switch to Dolutegravir\/Lamivudine vs Maintenance of Tenofovir Alafenamide\u2013Based Regimens"],"prefix":"10.1093","volume":"10","author":[{"given":"Rachel L","family":"Batterham","sequence":"first","affiliation":[{"name":"Department of Medicine, Centre for Obesity Research, University College London , London , UK"},{"name":"National Institute of Health Research, University College London Hospitals Biomedical Research Centre , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo , Sevilla, Andaluc\u00eda , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, INSERM\u2013Sorbonne Universit\u00e9s , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"McKellar","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scholten","sequence":"additional","affiliation":[{"name":"Praxis Hohenstaufenring , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don E","family":"Smith","sequence":"additional","affiliation":[{"name":"Albion Centre , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Ait-Khaled","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"George","sequence":"additional","affiliation":[{"name":"GSK , Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wright","sequence":"additional","affiliation":[{"name":"GSK , Brentford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A","family":"Gordon","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Moodley","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"2023072809212824700_ofad359-B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2016.10.004","article-title":"HIV and aging","volume":"53","author":"Wing","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2023072809212824700_ofad359-B2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/COH.0000000000000305","article-title":"HIV and ageing: improving quantity and quality of life","volume":"11","author":"Althoff","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2023072809212824700_ofad359-B3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18683\/germs.2017.1115","article-title":"2-Drug regimens in HIV treatment: pharmacological considerations","volume":"7","author":"Back","year":"2017","journal-title":"Germs"},{"key":"2023072809212824700_ofad359-B4","doi-asserted-by":"crossref","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023072809212824700_ofad359-B5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11904-016-0330-z","article-title":"Metabolic complications and glucose metabolism in HIV infection: a review of the evidence","volume":"13","author":"Willig","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023072809212824700_ofad359-B6","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services"},{"key":"2023072809212824700_ofad359-B7","article-title":"Guidelines version 11.0. October 2021","author":"European AIDS Clinical Society"},{"key":"2023072809212824700_ofad359-B8","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2023072809212824700_ofad359-B9","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a US cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023072809212824700_ofad359-B10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B11","doi-asserted-by":"crossref","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","article-title":"Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"6","author":"Schafer","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023072809212824700_ofad359-B12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/10600280211073321","article-title":"Weight changes with integrase strand transfer inhibitor therapy in the management of HIV infection: a systematic review","volume":"56","author":"Hester","year":"2022","journal-title":"Ann Pharmacother"},{"key":"2023072809212824700_ofad359-B13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-naive Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023072809212824700_ofad359-B15","article-title":"Early discontinuations and adverse events among treatment-naive patients initiating integrase inhibitors in a real-world setting [poster 889]","author":"Rolle"},{"key":"2023072809212824700_ofad359-B16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"N Engl J Med"},{"key":"2023072809212824700_ofad359-B17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/diacare.25.7.1135","article-title":"HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study","volume":"25","author":"Bonora","year":"2002","journal-title":"Diabetes Care"},{"key":"2023072809212824700_ofad359-B18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023072809212824700_ofad359-B19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","article-title":"Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population","volume":"75","author":"Drozd","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023072809212824700_ofad359-B20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV Infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2023072809212824700_ofad359-B21","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1007\/s10461-019-02487-8","article-title":"Metabolic syndrome among people living with HIV receiving medical care in southern United States: prevalence and risk factors","volume":"23","author":"Sears","year":"2019","journal-title":"AIDS Behav"},{"key":"2023072809212824700_ofad359-B22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2023072809212824700_ofad359-B24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QAI.0000000000000354","article-title":"Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy","volume":"67","author":"B\u00e9t\u00e9n\u00e9 A Dooko","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023072809212824700_ofad359-B26","doi-asserted-by":"crossref","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","article-title":"Inflammation, coagulation and cardiovascular disease in HIV-infected individuals","volume":"7","author":"Duprez","year":"2012","journal-title":"PLoS One"},{"key":"2023072809212824700_ofad359-B27","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/aid.2020.0247","article-title":"Expanding the Finnish Diabetes Risk Score for predicting diabetes incidence in people living with HIV","volume":"37","author":"Galaviz","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023072809212824700_ofad359-B29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1472-6823-13-47","article-title":"Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study","volume":"13","author":"Gayoso-Diz","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"2023072809212824700_ofad359-B30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1464-5491.2000.00280.x","article-title":"Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects: results from a cross-sectional study in Malm\u00f6, Sweden","volume":"17","author":"Hedblad","year":"2000","journal-title":"Diabet Med"},{"key":"2023072809212824700_ofad359-B31","volume-title":"The IDF consensus worldwide definition of the metabolic syndrome","author":"International Diabetes Federation","year":"2006"},{"key":"2023072809212824700_ofad359-B32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QAI.0000000000001942","article-title":"Etiology and severity of liver disease in HIV-positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies","volume":"80","author":"Iogna Prat","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023072809212824700_ofad359-B33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"2023072809212824700_ofad359-B34","doi-asserted-by":"crossref","first-page":"e25201","DOI":"10.1002\/jia2.25201","article-title":"Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy","volume":"21","author":"Perazzo","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2023072809212824700_ofad359-B35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"2023072809212824700_ofad359-B36","first-page":"838","article-title":"The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study","volume":"55","author":"Brindle","year":"2005","journal-title":"Br J Gen Pract"},{"key":"2023072809212824700_ofad359-B37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11904-021-00567-w","article-title":"Assessing cardiovascular risk in people living with HIV: current tools and limitations","volume":"18","author":"Achhra","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2023072809212824700_ofad359-B38","volume-title":"Strategies to prevent weight gain among adults. Comparative effectiveness review No. 97. AHRQ publication No. 13-EHC029-EF","author":"Hutfless","year":"2013"},{"key":"2023072809212824700_ofad359-B39","doi-asserted-by":"crossref","first-page":"585887","DOI":"10.3389\/fendo.2021.585887","article-title":"Leptin and obesity: role and clinical implication","volume":"12","author":"Obradovic","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023072809212824700_ofad359-B40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.physiol.62.1.413","article-title":"Leptin","volume":"62","author":"Ahima","year":"2000","journal-title":"Annu Rev Physiol"},{"key":"2023072809212824700_ofad359-B41","first-page":"3647","article-title":"Effects of weight change on plasma leptin concentrations and energy expenditure","volume":"82","author":"Rosenbaum","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2023072809212824700_ofad359-B42","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023072809212824700_ofad359-B43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2023072809212824700_ofad359-B44","article-title":"Weight gain after switching different integrase strand transfer inhibitors (InSTIs) [abstract 503]","author":"McComsey"},{"key":"2023072809212824700_ofad359-B45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/hiv.12984","article-title":"Dyslipidaemia after switch to tenofovir alafenamide (TAF)\u2013based cART regimens in a cohort of HIV-positive patients: what clinical relevance?","volume":"22","author":"Gazzola","year":"2021","journal-title":"HIV Med"},{"key":"2023072809212824700_ofad359-B46","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/QAI.0000000000002655","article-title":"Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide-based 3- or 4-drug regimen to the 2-drug regimen of dolutegravir\/lamivudine: the TANGO study","volume":"87","author":"van Wyk","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023072809212824700_ofad359-B47","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/oby.2010.59","article-title":"Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study","volume":"18","author":"Preis","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2023072809212824700_ofad359-B48","doi-asserted-by":"crossref","first-page":"e0190302","DOI":"10.1371\/journal.pone.0190302","article-title":"HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients","volume":"13","author":"Saracino","year":"2018","journal-title":"PLoS One"},{"key":"2023072809212824700_ofad359-B49","doi-asserted-by":"crossref","first-page":"ofac291","DOI":"10.1093\/ofid\/ofac291","article-title":"One in 10 virally suppressed persons with HIV in the Netherlands experiences \u226510% weight gain after switching to tenofovir alafenamide and\/or integrase strand transfer inhibitor","volume":"9","author":"Verburgh","year":"2022","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad359\/50860169\/ofad359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad359\/50982562\/ofad359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/7\/ofad359\/50982562\/ofad359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T09:22:44Z","timestamp":1690536164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad359\/7223126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad359","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7,1]]},"article-number":"ofad359"}}